Study summary · research use only
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses research on thymosin alpha 1 (T alpha 1) combined with other agents for cancer immunotherapy, covering both experimental and human studies. The authors describe evidence that combining T alpha 1 with low doses of interferon or interleukin-2 was associated with restoring immune responses that had been depressed by tumor growth or cytostatic drugs. When combined with chemotherapy, the authors report this approach was associated with an increased anti-tumor effect while reducing overall treatment toxicity. The review states that the advantages of this combined chemo-immunotherapeutic approach in experimental and human cancers are discussed in the issue, without providing additional numerical outcome data in this abstract.
Abstract
Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T alpha 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.